Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
You have been diagnosed with ductal carcinoma in-situ. On the one hand you know that DCIS is not breast cancer but on the other hand, you don’t want DCIS to develop into breast cancer. What do you do???
Several issues to consider. First, according to the study linked and excerpted below, the chances of getting BC in the same breast as your DCIS is 11.9% after 10 years. The chances that you will get breast cancer in the opposite breast is 4.6%.
But what if those risks are still too high for you? Yes, tamoxifen will reduce your risk of BC relapse further. And yes, whole breast radiation will lower your risk of BC relapse even further. Both of these therapies reduce your risk by a small percentage.
Unfortunately, both therapies can result in short, long-term and late-stage side effects. The collateral damage from these therapies is well-documented. Please ask your oncologist.
Most importantly, though the study linked and excerpted below cites a dizzying array of statistics related to 5 years, 10 years, contr, ipsa, etc. it does not say anything about the most important statistic of all. The effect of radiation has on overall survival. According to many studies, radiation does not improve overall survival for DCIS patients. Though the collateral damage caused by radiation can cause short, long-term and late-stage side effects it does not add to a woman’s OS.
There are a number of evidence-based, non-toxic therapies shown to reduce your risk of breast cancer- nutrition, supplementation, lifestyle, detoxification, etc. all have been shown by research to reduce the risks of BC.
To learn more about DCIS and the evidence-based therapies that can help you prevent its spread into invasive breast cancer, please watch the video below:
To download the DCIS Guide, click here.
I should know. I am a long-term survivor of a completely different cancer called multiple myeloma. MM is considered to be incurable by conventional oncology. I was first diagnosed with MM in early ’94 and reached complete remission in 4/99. I live an evidence-based, anti-MM lifestyle through nutrition, supplementation, etc.
For more information about evidence-based, non-toxic therapies to reduce your risk of BC, scroll down the page, post a question or a comment and I will reply to you ASAP.
“Relating to the opposite side, as when pain is perceived or paralysis occurs on the side opposite to that of the lesion.
“On the same side, as opposed to contralateral…”
“Fewer than 6% of women with ductal carcinoma in situ developed contralateral breast cancer within 10 years, according to study results presented at the American Society of Breast Surgeons Annual Meeting…
Contralateral breast cancer incidence did not appear associated with age, family history or characteristics of initial ductal carcinoma in situ (DCIS), nor did it appear associated with factors that increase ipsilateral breast tumor recurrence…
Therefore, Miller and colleagues conducted their study to quantify the rate of contralateral breast cancer among women with DCIS who underwent breast-conserving surgery; compare risk for contralateral breast cancer with that of ipsilateral breast tumor recurrence; identify factors associated with contralateral breast cancer risk; and evaluate whether those risk factors were the same as those for ipsilateral breast tumor recurrence…
During follow-up, 328 (11.9%) of women developed ipsilateral breast tumor recurrence and 127 (4.6%) developed contralateral breast cancer as their first breast event.
Researchers reported a higher cumulative incidence of ipsilateral breast tumor recurrence than contralateral breast cancer at 5 years (7.8% vs. 2.8%) and 10 years (14.3% vs. 5.6%)…
“For a woman undergoing breast-conserving surgery for DCIS, the 10-year ipsilateral breast tumor recurrence rate is 2.5-fold higher than the contralateral breast cancer rate,” Miller and colleagues wrote. “For a woman not receiving radiation therapy, the ipsilateral breast tumor recurrence rate is 4-fold higher than the contralateral breast cancer rate. Identification of factors associated with higher ipsilateral breast tumor recurrence risk may be important in decision-making between breast-conserving surgery and unilateral mastectomy, but should not prompt contralateral prophylactic mastectomy for DCIS.””